Mining The Cancer Genome Atlas (TCGA) Database to Identify Genotype Matched Tumor Suppressor microRNAs toward the Next Generation of Cancer Drugs Targeting the hedgehog signalling pathway in triple negative breast cancer Identification of a novel glucose oxidation agonist that selectively kills cancer cells PP2A - a novel biomarker and therapeutic target for poor outcome breast cancer Cell cycle checkpoint inhibition and cyclophosphamide is an effective combination therapy in a mouse model of paediatric medulloblastoma The glucocorticoid receptor coordinately regulates BIM and BCL2 in paediatric acute lymphoblastic leukaemia cells Establishing in vitro and in vivo models to develop novel therapeutic approaches for Diffuse Intrinsic Pontine Glioma. Targeting mitochondrial function and the PI3K/AKT/mTOR pathway as a novel therapeutic approach in the treatment of Diffuse Intrinsic Pontine Glioma Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA activation and transendothelial migration Identification of CIP2A as a Prognostic Marker and a Therapeutic Target in Glioblastoma Global Phosphoproteomic Mapping Reveals How Phosphatases Control Mitotic Exit And Maintain Genome Stability High-throughput screening identifies new inhibitors of the multidrug transporter MRP4 MYCN coordinately regulates the entire polyamine pathway to maintain high polyamine levels in neuroblastoma A comprehensive and systematic analysis of miRNA function in neuroblastoma  Novel approaches to targeting the tumour-stroma coalition in triple negative breast cancers Molecular profiling to predict drug sensitivity or resistance in relapsed childhood cancer Targeting copper metabolism in neuroblastoma using Dextran-Catechin An 18-gene Myc activity signature for neuroblastoma and other Myc-driven cancers Involvement of ATM in the recruitment of human telomerase to telomeres Reactivating the p53 stress response to treat oesophageal cancer Molecular diagnostics in pediatric (neuro-) onclology in the omics era Identification of a novel compound that synergistically inhibits cell growth with BRAF inhibitor in BRAF wildtype and NRAS mutant melanoma cells MEK inhibition and models of resistance in acute myeloid leukaemia. The prorenin receptor as a novel therapeutic target for the treatment of endometrial cancer A new cancer therapeutic that targets angiogenic vessels